TY - JOUR
T1 - Efficacy and safety of Si-Jun-Zi-Tang-based therapies for functional (non-ulcer) dyspepsia
T2 - a meta-analysis of randomized controlled trials
AU - Wang, Yaping
AU - Liu, Bin
AU - Fu, Xiuqiong
AU - Tong, Tiejun
AU - Yu, Zhiling
N1 - Funding Information:
This work was supported by Guangdong Provincial Department of Science and Technology (2016A030313007), Food and Health Bureau of Hong Kong (HMRF14150571 and HMRF04150476), National Natural Science Foundation of China (81673649, 81803788 and 81874358), Shenzhen Science and Technology Innovation Commission (JCYJ20160229210327924 and JCYJ20170817173608483), Research Grants Council of Hong Kong (GRF12125116 and GRF12102918), and Hong Kong Baptist University (FRG1/16–17/048, FRG2/17–18/032 and RC-IG-FNRA/17–18/13). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher copyright:
© The Author(s). 2020
PY - 2021/12
Y1 - 2021/12
N2 - Background: The traditional Chinese medicine formula Si-Jun-Zi-Tang (SJZT) has a long history of application in the treatment of functional dyspepsia (non-ulcer dyspepsia, FD)-like symptoms. SJZT-based therapies have been claimed to be beneficial in managing FD. This study aimed to assess the efficacy and safety of SJZT-based therapies in treating FD by meta-analysis.Methods: Systematic searches for RCTs were conducted in seven databases (up to February 2019) without language restrictions. Data were analyzed using Cochrane RevMan software version 5.3.0 and Stata software version 13.1, and reported as relative risk (RR) or odds ratio (OR) with 95% confidence intervals (CIs). The primary outcome was response rate and the secondary outcomes were gastric emptying, quality of life, adverse effects and relapse rate. The quality of evidence was evaluated according to criteria from the Cochrane risk of bias.Results: A total of 341 potentially relevant publications were identified, and 12 RCTs were eligible for inclusion. For the response rate, there was a statically significant benefit in favor of SJZT-based therapies (RR = 1.23; 95% CI 1.17 to 1.30). However, the benefit was limited to modified SJZT (MSJZT). The relapse rate of FD patients received SJZT-based therapies was lower than that of patients who received conventional medicines (OR = 0.23; 95% CI 0.10 to 0.51). No SJZT-based therapies-related adverse effect was reported.Conclusion: SJZT-based prescriptions may be effective in treating FD and no serious side-effects were identified, but the effect on response rate appeared to be limited to MSJZT. The results should be interpreted with caution as all the included studies were considered at a high risk of bias. Standardized, large-scale and strictly designed RCTs are needed to further validate the benefits of SJZT-based therapies for FD management.
AB - Background: The traditional Chinese medicine formula Si-Jun-Zi-Tang (SJZT) has a long history of application in the treatment of functional dyspepsia (non-ulcer dyspepsia, FD)-like symptoms. SJZT-based therapies have been claimed to be beneficial in managing FD. This study aimed to assess the efficacy and safety of SJZT-based therapies in treating FD by meta-analysis.Methods: Systematic searches for RCTs were conducted in seven databases (up to February 2019) without language restrictions. Data were analyzed using Cochrane RevMan software version 5.3.0 and Stata software version 13.1, and reported as relative risk (RR) or odds ratio (OR) with 95% confidence intervals (CIs). The primary outcome was response rate and the secondary outcomes were gastric emptying, quality of life, adverse effects and relapse rate. The quality of evidence was evaluated according to criteria from the Cochrane risk of bias.Results: A total of 341 potentially relevant publications were identified, and 12 RCTs were eligible for inclusion. For the response rate, there was a statically significant benefit in favor of SJZT-based therapies (RR = 1.23; 95% CI 1.17 to 1.30). However, the benefit was limited to modified SJZT (MSJZT). The relapse rate of FD patients received SJZT-based therapies was lower than that of patients who received conventional medicines (OR = 0.23; 95% CI 0.10 to 0.51). No SJZT-based therapies-related adverse effect was reported.Conclusion: SJZT-based prescriptions may be effective in treating FD and no serious side-effects were identified, but the effect on response rate appeared to be limited to MSJZT. The results should be interpreted with caution as all the included studies were considered at a high risk of bias. Standardized, large-scale and strictly designed RCTs are needed to further validate the benefits of SJZT-based therapies for FD management.
KW - Efficacy
KW - Functional (non-ulcer) dyspepsia
KW - Meta-analysis
KW - Safety
KW - Si-Jun-Zi-tang
KW - Traditional Chinese medicine
UR - http://www.scopus.com/inward/record.url?scp=85099063708&partnerID=8YFLogxK
U2 - 10.1186/s12906-020-03176-z
DO - 10.1186/s12906-020-03176-z
M3 - Journal article
C2 - 33407405
AN - SCOPUS:85099063708
SN - 2662-7671
VL - 21
JO - BMC Complementary Medicine and Therapies
JF - BMC Complementary Medicine and Therapies
IS - 1
M1 - 11
ER -